Christopher Marai
Stock Analyst at Nomura
(1.56)
# 1,431
Out of 4,653 analysts
33
Total ratings
54.55%
Success rate
11.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Marai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $360 → $960 | $17.55 | +5,370.09% | 2 | Jun 4, 2020 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $29 → $33 | $41.04 | -19.59% | 2 | May 11, 2020 | |
| SLDB Solid Biosciences | Maintains: Buy | $150 → $90 | $5.31 | +1,594.92% | 5 | May 8, 2020 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Reduce | $74 | $257.91 | -71.31% | 4 | Apr 14, 2020 | |
| VYGR Voyager Therapeutics | Maintains: Buy | $37 → $16 | $6.22 | +157.23% | 2 | Mar 30, 2020 | |
| BIIB Biogen | Maintains: Buy | $320 → $392 | $164.89 | +137.73% | 7 | Feb 7, 2020 | |
| BYSI BeyondSpring | Initiates: Buy | $34 | $1.73 | +1,869.87% | 1 | Jan 10, 2020 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $205 → $230 | $109.11 | +110.80% | 3 | Feb 28, 2019 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $22 → $12 | $16.79 | -28.53% | 3 | Dec 17, 2018 | |
| PRTA Prothena Corporation | Maintains: Buy | $87 → $19 | $16.10 | +18.01% | 2 | Apr 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $49 → $43 | $1.91 | +2,151.31% | 2 | Sep 6, 2017 |
Corbus Pharmaceuticals Holdings
Jun 4, 2020
Maintains: Buy
Price Target: $360 → $960
Current: $17.55
Upside: +5,370.09%
Protagonist Therapeutics
May 11, 2020
Maintains: Buy
Price Target: $29 → $33
Current: $41.04
Upside: -19.59%
Solid Biosciences
May 8, 2020
Maintains: Buy
Price Target: $150 → $90
Current: $5.31
Upside: +1,594.92%
Alnylam Pharmaceuticals
Apr 14, 2020
Maintains: Reduce
Price Target: $74
Current: $257.91
Upside: -71.31%
Voyager Therapeutics
Mar 30, 2020
Maintains: Buy
Price Target: $37 → $16
Current: $6.22
Upside: +157.23%
Biogen
Feb 7, 2020
Maintains: Buy
Price Target: $320 → $392
Current: $164.89
Upside: +137.73%
BeyondSpring
Jan 10, 2020
Initiates: Buy
Price Target: $34
Current: $1.73
Upside: +1,869.87%
Sarepta Therapeutics
Feb 28, 2019
Maintains: Buy
Price Target: $205 → $230
Current: $109.11
Upside: +110.80%
Syndax Pharmaceuticals
Dec 17, 2018
Maintains: Buy
Price Target: $22 → $12
Current: $16.79
Upside: -28.53%
Prothena Corporation
Apr 24, 2018
Maintains: Buy
Price Target: $87 → $19
Current: $16.10
Upside: +18.01%
Sep 6, 2017
Maintains: Buy
Price Target: $49 → $43
Current: $1.91
Upside: +2,151.31%